Literature DB >> 17325236

Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure?

Thomas Münzel, Sabine Genth-Zotz, Ulrich Hink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17325236     DOI： 10.1161/HYPERTENSIONAHA.106.085456

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  14 in total

Review 1.  Soluble guanylate cyclase: a potential therapeutic target for heart failure.

Authors:  Mihai Gheorghiade; Catherine N Marti; Hani N Sabbah; Lothar Roessig; Stephen J Greene; Michael Böhm; John C Burnett; Umberto Campia; John G F Cleland; Sean P Collins; Gregg C Fonarow; Phillip D Levy; Marco Metra; Bertram Pitt; Piotr Ponikowski; Naoki Sato; Adriaan A Voors; Johannes-Peter Stasch; Javed Butler
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

Review 2.  Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects.

Authors:  Qingwu Kong; Robert M Blanton
Journal:  Circ Heart Fail       Date:  2013-11       Impact factor: 8.790

3.  Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation.

Authors:  Allan W Jones; William Durante; Ronald J Korthuis
Journal:  J Pharmacol Exp Ther       Date:  2010-07-06       Impact factor: 4.030

4.  Soluble guanylate cyclase activation during ischemic injury in mice protects against postischemic inflammation at the mitochondrial level.

Authors:  Derek Z Wang; Allan W Jones; Walter Z Wang; Meifang Wang; Ronald J Korthuis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-02-25       Impact factor: 4.052

Review 5.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.

Authors:  Walter Z Wang; Allan W Jones; Meifang Wang; William Durante; Ronald J Korthuis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-06-14       Impact factor: 4.733

7.  Soluble Guanylate Cyclase Stimulators and Activators.

Authors:  Peter Sandner; Daniel P Zimmer; G Todd Milne; Markus Follmann; Adrian Hobbs; Johannes-Peter Stasch
Journal:  Handb Exp Pharmacol       Date:  2021

8.  Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.

Authors:  L S Hoffmann; P M Schmidt; Y Keim; S Schaefer; H H H W Schmidt; J P Stasch
Journal:  Br J Pharmacol       Date:  2009-05-18       Impact factor: 8.739

Review 9.  Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials.

Authors:  Prabhjot Singh; Shilpa Vijayakumar; Andreas Kalogeroupoulos; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2018-04

Review 10.  Deregulation of RGS2 in cardiovascular diseases.

Authors:  Sharon Tsang; Anthony Yiu-Ho Woo; Weizhong Zhu; Rui-Ping Xiao
Journal:  Front Biosci (Schol Ed)       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.